MapLight Therapeutics, Inc. cash flow statement MPLT

In fiscal 2025, which ended Dec 31, 2025, MapLight Therapeutics, Inc. used $138.1 million of cash from operations. It spent $473,000 on capital expenditures. Free cash flow was negative, at -$138.6 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
—
1
Stock-based compensation
—
36
Operating cash flow
—
-138
Investing
Capital expenditures
—
0
Investing cash flow
—
-323
Financing
Financing cash flow
—
470
Change in cash
Free cash flow
—
-139
Per share
Free cash flow per share
—
-15.97
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MPLT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Redwood City, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1770069
Former names
Alvarado Therapeutics, Inc. (until Mar 22, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.